Our focus is on the discovery and development of proprietary small molecule drugs for inflammation and respiratory diseases related to bioactive lipid pathways.

We look to out license primary care indications for the drugs we discover, generally following proof of concept and before later-stage clinical trials. We plan to retain and commercialize certain specialty of niche indications for selected compounds.

As we move forward, we expect to expand our discovery and development to additional, related bioactive lipid pathways.